<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>313</serviceExecutionTime><Drug id="54387"><DrugName>icatibant (inhaled, asthma), Jerini/Abbott</DrugName><DrugNamesKey><Name id="42815234">icatibant</Name></DrugNamesKey><DrugSynonyms><Name><Value>icatibant</Value><Types><Type>INN</Type></Types></Name><Name><Value>icatibant (inhaled, asthma), Jerini/Kos Pharmaceuticals</Value></Name><Name><Value>icatibant (inhaled, asthma), Abbott</Value></Name><Name><Value>icatibant (inhaled, asthma), Jerini/Abbott</Value></Name><Name><Value>130308-48-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1009547">Sanofi SA</CompanyOriginator><CompaniesSecondary><Company id="1009547">Sanofi SA</Company><Company id="13601">Abbott Laboratories</Company><Company id="21507">Kos Pharmaceuticals Inc</Company><Company id="29210">Shire Orphan Therapies GmbH</Company></CompaniesSecondary><CrossReferences><SourceEntity id="54387" type="Drug"><TargetEntity id="166737" type="siDrug">Icatibant acetate</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="21507" type="Company"><TargetEntity id="4295906935" type="organizationId">Kos Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="29210" type="Company"><TargetEntity id="4295870184" type="organizationId">Jerini AG</TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="789" type="Action"><TargetEntity id="97" type="Mechanism">Bradykinin B2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00225" type="ciTarget"><TargetEntity id="8141049666243" type="siTarget">B2 bradykinin receptor</TargetEntity><TargetEntity id="-1941307240" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="CU">Clinical</PhaseTerminated><IndicationsSecondary><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsPrimary><Action id="789">Bradykinin B2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2017-08-21T11:24:01.000Z</LastModificationDate><ChangeDateLast>2018-11-13T00:00:00.000Z</ChangeDateLast><AddedDate>2005-11-07T14:41:45.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29210" linkType="Company"&gt;Jerini&lt;/ulink&gt; and &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="21507" linkType="Company"&gt;Kos Pharmaceuticals&lt;/ulink&gt; in December 2006 [&lt;ulink linkID="751915" linkType="Reference"&gt;751915&lt;/ulink&gt;], under license from &lt;ulink linkID="1009547" linkType="Company"&gt;sanofi-aventis&lt;/ulink&gt; (formerly &lt;ulink linkID="27254" linkType="Company"&gt;Aventis&lt;/ulink&gt;), were developing an inhaled formulation of  the selective bradykinin  B2 antagonist &lt;ulink linkID="3310" linkType="Drug"&gt;icatibant&lt;/ulink&gt;  as a potential  treatment for asthma [&lt;ulink linkID="632721" linkType="Reference"&gt;632721&lt;/ulink&gt;]&lt;b&gt;.&lt;/b&gt; By November 2005, proof-of-concept trials were complete [&lt;ulink linkID="632721" linkType="Reference"&gt;632721&lt;/ulink&gt;]. However, by May 2008, the inhaled icatibant program was no longer listed on Jerini's pipeline and it was presumed to have been discontinued [&lt;ulink linkID="913840" linkType="Reference"&gt;913840&lt;/ulink&gt;]. In September 2007, Kos had returned the rights to the compound to Jerini [&lt;ulink linkID="827590" linkType="Reference"&gt;827590&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Jerini is developing an &lt;ulink linkID="3310" linkType="Drug"&gt;injectable formulation of icatibant&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By November 2005, proof-of-concept trials had been completed for asthma [&lt;ulink linkID="632721" linkType="Reference"&gt;632721&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2005, Kos Pharmaceuticals  signed an exclusive agreement with Jerini to develop, market and distribute icatibant  in North America.  In addition to hereditary angioedema, the agreement also provided collaboration options for other forms of angioedema, asthma and refractory ascites in liver cirrhosis [&lt;ulink linkID="632721" linkType="Reference"&gt;632721&lt;/ulink&gt;]. However, in September 2007, Kos returned  the rights to the drug to Jerini, following the decision made by its parent company, &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt;, that icatibant was not a strategic  fit with the company's core therapeutic areas [&lt;ulink linkID="827590" linkType="Reference"&gt;827590&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2001, Aventis and Jerini formed a licensing agreement under which Jerini gained an exclusive, worldwide, royalty-bearing license to develop icatibant [&lt;ulink linkID="429658" linkType="Reference"&gt;429658&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29210">Shire Orphan Therapies GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2008-05-04T00:00:00.000Z</StatusDate><Source id="913840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2008-05-04T00:00:00.000Z</StatusDate><Source id="913840" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2001-11-16T00:00:00.000Z</StatusDate><Source id="429658" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2005-11-07T00:00:00.000Z</StatusDate><Source id="632721" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2006-12-15T00:00:00.000Z</StatusDate><Source id="751915" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29210">Shire Orphan Therapies GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2005-11-07T00:00:00.000Z</StatusDate><Source id="632721" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00225"><Name>Bradykinin B2 receptor</Name><SwissprotNumbers><Swissprot>O70526</Swissprot><Swissprot>P25023</Swissprot><Swissprot>P30411</Swissprot><Swissprot>P32299</Swissprot><Swissprot>Q28642</Swissprot><Swissprot>Q9GLX8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="30624">Bachem Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc2c(c1)C[C@@H](N(C2)C(=O)[C@H](CO)NC(=O)[C@H](Cc3cccs3)NC(=O)CNC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O)C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(=N)N)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="108602" title="Kos Pharmaceuticals to develop Jerini's icatibant formulations in North America"/><Deal id="110223" title="Jerini to develop Aventis's icatibant"/><Deal id="120000" title="Bachem to supply icatibant to Jerini"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>